 Mereo BioPharma Group plc NASDAQ: MREO, AIM: MPH, Mereo or the Company, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointments of John Lewicki, PhD, as Chief Scientific Officer, and Ann Kapoun, PhD, as Senior Vice President SVP of Translational Research and Development. Drs. Lewicki and Kapoun join Mereo having previously served tenures at OncoMed Pharmaceuticals and were involved in the discovery and development of etigilimab Anti-TIGIT, prior to the 2019 merger of OncoMed and Mereo BioPharma. 